By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel consensus is that the Bridge program for obesity drugs is structurally bullish for Novo Nordisk and Eli Lilly long-term, but operationally messy near-term. The primary risk is the slow uptake due to administrative hurdles, lack of public awareness, and potential policy reversals if spending increases draw attention. The key opportunity is the expansion of the covered patient pool, with a potential multi-billion dollar total addressable market unlock.
Risk: Slow uptake due to administrative hurdles and potential policy reversals
Opportunity: Expansion of the covered patient pool with a potential multi-billion dollar total addressable market unlock
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift may be flying under the radar for many of them.
Starting Wednesday, eligible beneficiaries can get obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. The coverage marks a long-sought victory for patients, physicians and obesity advocates who have pushed for broader access to the blockbuster treatments from Novo Nordisk and Eli Lilly, which have remained out of reach for many Americans.
But a staggering 82% of all older Americans — including 79% of Republicans and 84% of Democrats — say they are unaware that Medicare is about to begin covering obesity drugs, according to a survey released in early June by the Obesity Care Advocacy Network. The survey, conducted in late March among more than 2,100 adults ages 65 and older, was completed weeks before the government announced it would extend the Bridge program through 2027.
That data may not come as a surprise: While the government has done robust outreach to healthcare providers and pharmacists, some physicians and other experts told CNBC that they have noticed limited advertising of the new coverage to the general public from the Centers for Medicare & Medicaid Services or Novo and Lilly.
There may be good reasons for it. CMS has done limited public outreach on the program ahead of July 1 because beneficiaries are "most moved to take action" when a benefit is actually available to them, an agency official told reporters on Thursday. They added that CMS will put out more promotions after the launch, "in the interest of being good stewards of our taxpayer dollars."
Other experts also told CNBC that it may come down to making sure providers and pharmacies are prepared and resources are in place before pursuing broad public outreach.
Still, some experts say the lack of awareness may delay some eligible adults from taking advantage of the new coverage and getting on the treatments immediately.
"I have not seen a lot of information out there for the public, and I think there are going to be plenty of people who have zero knowledge of the Bridge program," said Dr. Shauna Levy, medical director of the Tulane Bariatric and Weight Loss Center. "And I think for patients, it's just going to take even longer for them to find out about it, and then see if they're eligible."
Unlike traditional Medicare drug coverage, enrollment in the Bridge program is not automatic. Patients must meet eligibility requirements, obtain a prescription and receive prior authorization approval through CMS before coverage begins.
The relatively quiet lead-up to the rollout stands in contrast to the marketing campaigns Novo and Lilly have historically deployed for their obesity and diabetes medicines, which have appeared everywhere from television commercials to subway advertisements.
Novo spent nearly $500 million on U.S. advertising for its obesity drug Wegovy and its diabetes counterpart Ozempic in the first 9 months of 2025, more than double the just over $200 million Lilly spent promoting its rival injections, Zepbound and Mounjaro, Reuters reported, citing data from the ad-tracking firm MediaRadar.
"I was a little surprised that there hasn't been more advertising by Lilly and Novo for seniors to be ready to get their prescription," said Leerink Partners analyst David Risinger, adding that it takes time to book an appointment with a provider to obtain one.
Medicare beneficiaries must be enrolled in Part D, a prescription drug plan, to qualify for the new coverage. But because the Bridge program is administered directly by CMS rather than through Part D plans, private insurers don't need to play a role in educating beneficiaries about the new coverage.
"All of that marketing advantage of having it run through the Part D plans doesn't exist," said Kenneth Thorpe, health policy professor at Emory University.
He said "getting the word out" about the program and who is eligible will likely be among the largest challenges of the rollout.
The eligibility for the program is broad, but certain patients will not qualify. That includes those already receiving coverage of a GLP-1 from their Part D plan for a use already covered by Medicare, such as Type 2 diabetes, cardiovascular disease risk reduction or sleep apnea.
While advertising of the GLP-1 coverage may not mirror previous rollouts, there has been some promotion ahead of the launch.
Targeted mentions on social media and Novo's website are advertising the Bridge program, said Jamey Millar, the company's executive vice president of U.S. operations, in an interview on Wednesday.
He acknowledged that no linear TV ads are promoting the new coverage, but said he believes awareness among patients will come from providers and pharmacies. CMS has done comprehensive outreach to both about the upcoming program, according to some physicians.
Millar likened the dynamic to the annual flu vaccine or shingles shot for older adults.
"Any seniors that walk into a retail pharmacy post-July 1, on average, they're on eight medications, most of them oral, so the pharmacist has an opportunity to say, did you know about Bridge?" he told CNBC. "So they're equipped to do it, and then [health-care providers] as well."
The limited public outreach ahead of July 1 may be by design. A slower rollout could give physicians, pharmacies and CMS time to prepare before a potentially large number of beneficiaries begin seeking treatment.
"We typically take the view that let's make sure that the physicians are prepared, similar to what we did with Foundayo, before getting broad awareness for consumers," Ilya Yuffa, president of Lilly USA and global customer capabilities, said in an interview on Wednesday.
Yuffa was referring to the recent launch of Lilly's obesity pill, Foundayo. Building awareness among providers and the broader healthcare system first helps avoid "friction" between patients and physicians, he said.
Still, Yuffa said consumers should expect to see broader marketing efforts from Lilly around the availability of Foundayo and one form of Zepbound through the Bridge program.
Some experts suggested CMS may also be trying to ensure the program can handle an influx of interest. Beneficiaries must obtain prior authorization before receiving coverage, and processing those requests could become a significant undertaking if demand surges immediately after launch.
"It may be, let's get the first month down and see what mistakes we make, so we can fix it, rather than everything crashes and burns within a month or two," said Dr. Holly Lofton, director of the Medical Weight Management Program at NYU Langone.
"The thing is, the access is there, and hopefully the world will get around," she said.
Four leading AI models discuss this article
"The real upside hinges on rapid provider/pharmacy onboarding and durable patient access; otherwise the headline expansion may yield only a modest near-term demand lift."
While the Bridge program makes obesity drugs cheaper for seniors, the narrative may overstate impact. Uptake depends on (1) whether prior authorization and prescription routes move smoothly, (2) public awareness among beneficiaries, and (3) whether the program proves durable beyond 2027. The article notes limited public advertising and an administrative process that isn’t automatic, suggesting uptake could lag. Supply constraints, clinician hesitancy, and the need for ongoing obesity-management beyond drug therapy could cap short-term demand. For Novo Nordisk and Lilly, this could mean a slow, staged lift in sales rather than an immediate surge.
The strongest counter is that uptake may be slower than portrayed due to administrative hurdles and limited outreach; plus the program’s temporary nature risks delivering only a transient bump, not a durable revenue lift.
"The requirement for individual prior authorization, combined with the exclusion of existing diabetic beneficiaries, will act as a significant structural brake on the immediate revenue growth expected from this Medicare coverage expansion."
The market is underestimating the friction in this 'Bridge' rollout. While the headline suggests a demand surge for Novo Nordisk (NVO) and Eli Lilly (LLY), the requirement for individual prior authorization (PA) and the exclusion of patients already covered for diabetes or cardiovascular risk creates a massive administrative bottleneck. CMS is intentionally throttling awareness to prevent a system crash, but this effectively caps the immediate TAM expansion. Investors should watch the 'prior authorization approval rate' as a key KPI; if it remains low due to bureaucratic complexity, the revenue impact for 2024 will be negligible. This isn't a demand problem; it's a supply-chain and regulatory execution risk.
The 'friction' is a feature, not a bug; by limiting initial uptake, CMS and the manufacturers are successfully managing the supply shortage while building a sustainable, long-term reimbursement pathway that avoids the political backlash of a sudden, uncontrolled Medicare budget explosion.
"The Bridge program is a genuine market expansion, but the 82% unawareness + prior auth gatekeeping means 2025 revenue contribution will be materially lower than consensus models assume, creating a near-term disappointment risk despite long-term bullishness."
This is structurally bullish for NVO and LLY long-term but operationally messy near-term. The $50 copay removes the primary access barrier for ~45M Medicare beneficiaries—a multi-billion TAM unlock. However, the article reveals a critical execution risk: 82% unawareness + no automatic enrollment + prior auth requirements create a demand cliff. The deliberate slow rollout may prevent system collapse, but it also means Q3-Q4 2025 uptake will likely disappoint versus what the market has priced in. The real question isn't whether this is transformative—it is—but whether the Street expects 2025-2026 revenue acceleration that won't materialize due to friction.
If CMS and the manufacturers are intentionally throttling awareness to avoid system failure, that's an admission the program infrastructure is fragile. A slower ramp-up also gives private insurers and PBMs time to lobby Congress to kill or restrict the Bridge program before it becomes entrenched—the political window for reversal is narrowest when adoption is still low.
"Low awareness plus manual enrollment will push meaningful Medicare-driven volume for Wegovy and Zepbound into 2026 rather than delivering an immediate boost."
Medicare's Bridge program opens a large new pool of covered patients for GLP-1s, yet the rollout's deliberate quiet phase, non-automatic enrollment, prior-authorization gate, and 82% unawareness rate among seniors point to a slower revenue ramp than headline coverage suggests. Novo and Lilly have historically relied on direct-to-consumer ads that are absent here; instead, uptake hinges on pharmacists and physicians spotting eligible Part D members during routine visits. This creates a multi-quarter lag before scripts accelerate, even if the $50 copay removes price barriers for qualifying patients. Capacity constraints at CMS for authorizations add further friction that could cap 2025-2026 sales upside.
The program could see faster adoption if retail pharmacies proactively flag patients post-July 1, turning the lack of TV ads into a non-issue and driving quicker script growth than modeled.
"Policy backlash and tighter coverage could cap near-term uptake, making the Bridge ramp riskier than the friction-focused view implies."
To Gemini: Friction as a feature understates the political economy. If 2025-26 uptake disappoints, Medicare beneficiaries’ rising spending on GLP-1s will draw attention from policymakers and payers, increasing pressure to tighten coverage or curb access. Incremental opt-in and authorizations may become a target rather than a safety valve, risking a sharper policy reversal than the market expects. The risk curve is asymmetric: slow ramp today could trigger a bigger funding cliff tomorrow.
"PBMs will weaponize prior authorization requirements to protect their rebate-driven business models, creating a structural barrier to adoption regardless of CMS's stated goals."
Claude and Grok are missing the PBM (Pharmacy Benefit Manager) incentive structure. PBMs are the real gatekeepers here, not just administrative friction. They have zero incentive to facilitate a 'Bridge' program that bypasses their negotiated rebates. If PBMs perceive this program as a threat to their formulary control, they will weaponize the prior authorization process to block access, regardless of CMS intent. This isn't just a supply-side bottleneck; it is a structural conflict of interest.
"PBMs will ration, not block—using PA friction to control velocity while maintaining rebate leverage."
Gemini's PBM incentive argument is sharp, but overstates their power here. PBMs profit from volume and rebates; blocking a $50 copay program that expands their covered lives actually increases their negotiating leverage with manufacturers. The real risk: PBMs use PA delays tactically—not to block, but to ration uptake and preserve scarcity value. That's subtly different and harder to detect than outright gatekeeping.
"Low uptake plus the 2027 cliff creates a self-reinforcing political exit ramp rather than a durable reimbursement path."
Gemini's PBM-as-weapon claim overlooks how the Bridge program's carve-out for non-diabetes patients actually preserves PBM rebate streams on existing scripts. The real linkage nobody flagged is between ChatGPT's political reversal risk and the 2027 sunset: if uptake stays low through 2026, Congress has little incentive to extend funding, turning the temporary bridge into a one-time test that manufacturers must over-invest to make permanent.
The panel consensus is that the Bridge program for obesity drugs is structurally bullish for Novo Nordisk and Eli Lilly long-term, but operationally messy near-term. The primary risk is the slow uptake due to administrative hurdles, lack of public awareness, and potential policy reversals if spending increases draw attention. The key opportunity is the expansion of the covered patient pool, with a potential multi-billion dollar total addressable market unlock.
Expansion of the covered patient pool with a potential multi-billion dollar total addressable market unlock
Slow uptake due to administrative hurdles and potential policy reversals